Navigation Links
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Date:6/5/2009

SEATTLE, June 5 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following two investor conferences next week.

    Goldman Sachs 30th Annual Global Healthcare Conference
    Tuesday, June 9, 2009
    4:20 p.m. ET

    8th Annual Needham Life Sciences Conference
    Thursday, June 11, 2009
    11:00 a.m. ET

The presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
2. Dendreon Announces Closing of Common Stock Offering
3. Dendreon Announces Common Stock Offering
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports First Quarter 2009 Financial Results
6. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
7. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
8. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
9. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
10. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
11. Dendreon Reports Third Quarter 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...wswire/--CromozInc.,locatedinResearchTrianglePark,...rdrugdeliverysysteminHyderabad,India.Thewater-solu...allsthatallowsforconjugationwithcancerdrugs,wasdev...ITT).Theconjugatedcarbonnanotubesservesasadrugdeli...hhasthepotentialtoincreasethedrugefficacy. ,, T...
(Date:11/27/2009)...wire-FirstCall/--Stallergeneshasbeen,grantedEurope...n,throughaMutualRecognitionProcedure.Germany,thefi...ferenceMemberstate. , Oralair(R)isnowregister...lic,Estonia,France,Germany,Greece,Hungary,Ireland,...lands,Poland,Portugal,Romania,Slovakia,Slovenia,a...
(Date:11/27/2009)...hanised blue dye test alternative is helping bri...nce one step closer for pharma-companies. It is a ...e developed by Sepha for use with blister packs ... and global pharma-companies such as Sanofi-Avenis...d productivity improvements on the packaging line....
(Date:11/26/2009)...new generation of ultrasmall transistors and more ...ed semiconducting nanowires are closer to reality ...e University and the University of California at L...o create nanowires with layers of different materi...which is a critical requirement for making efficie...
Breaking Biology Technology:North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3
... 29, 2009 Senomyx, Inc. (Nasdaq: SNMX ) will re... and fiscal year ending December 31, 2008 on Thurs....S. financial markets. The Company will also host...11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) t...nt will provide a business update and will discuss...
... Sigma-Aldrich (Nasdaq: SIAL ),today announced ...PC,Scientific, a leading provider of high quality ... APIs for the pharmaceutical and biotechnology ind...tific will offer Sigma-Aldrich,s,PEPscreen(R) cust...een ) to life,science researchers and pharmaceutic...
...9 Amicus Therapeutics (Nasdaq: FOLD ) will anno...esults after the regular close of markets on Thurs...ll be followed by a live conference call and webca...participants and investors may access the conferen..../Canada) or 719-325-4870 (international). A telep...
Other Biology Technology:SENOMYX, INC. fourth quarter AND FISCAL YEAR-END 2008 Earnings conference call scheduled for February 12, 2009 2Sigma-Aldrich Signs Agreement With CPC Scientific for the Distribution of PEPscreen(R) Custom Peptide Libraries 2Sigma-Aldrich Signs Agreement With CPC Scientific for the Distribution of PEPscreen(R) Custom Peptide Libraries 3Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date 2
(Date:11/26/2009)...n,s most distinctive residents. ,Everyone wants to..., says Michelle McComb from Florida Atlantic Unive...,Perhaps their visual field has been enhanced by t...arks excellent stereovision and depth perception. ...ls of thought on this theory. In 1942, G. Walls sp...
(Date:11/26/2009)...ed deer have been caught in the hunters, sights fo...than decorative. They are lethal weapons that stag...The University of York, UK, has been intrigued by ...century and has become fascinated by the mechanica...laboration with Tomas Landete-Castillejos at the U...
(Date:11/26/2009)...ay of using recordings of birdsong to accurately m...irst time sound recordings from a microphone array...ird species, populations. Because the new techniqu...ournal of Applied Ecology , will also work with wh...ability to monitor whale and dolphin numbers. , ...
Breaking Biology News(10 mins):Wide heads give hammerheads exceptional stereo view 2Tough yet stiff deer antler is materials scientist's dream 2Ecologists sound out new solution for monitoring cryptic species 2Florida 26apos 3Bs Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10 Story Emergency Facility 59788 1Florida 26apos 3Bs Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10 Story Emergency Facility 59788 2Florida 26apos 3Bs Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10 Story Emergency Facility 59788 3Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 1Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 2Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 3Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 4Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 5Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 6Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 7Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 8Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 9Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 10Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 11Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 12Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 13Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 14Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 15LIVESTRONG 28R 29 Receives 24211 306 Donation from Eagle Golf 59782 1LIVESTRONG 28R 29 Receives 24211 306 Donation from Eagle Golf 59782 2
... of the worlds leading STM publishers, has signed ...ntific societies during the past half year. With ...resentative selection of Korean society journals a...blishing the increasing amount of research coming ... journals in 2008 were signed with the Korean Soci...
...rents need to be educated about managing fever in ...ectly and often unnecessarily, according to a Quee.... , QUT senior research fellow Anne Walsh conduct...nage childhood fever as part of her PhD. , Her re...iatrics and Child Health. , Ms Walsh found that, ...
...TE, Ind. - Researchers have developed a breed of A...light that decimated its population in the early 1...o-called for its picturesque form and towering hei...lew of obstacles, said a Purdue University researc...t blight, but there is a whole new set of obstacle...
Other Biology News:Fever causing headaches for Aussie parents 2Challenges remain in reintroducing American chestnut 2Challenges remain in reintroducing American chestnut 3
... expression profiling and built on the flexible an...platform. These microarrays are available as part ... Service. Probe Content The Fishes microRNA Mic...que mature sequences). The comprehensive probe con...
... expression profiling and built on the flexible an...platform. These microarrays are available as part ... Service. Probe Content The Maize microRNA Micr...ue mature sequences). The comprehensive probe cont...
...itative and qualitative capabilities of the 4000 Q...w Tempo nano MDLC System plus automation software,...validation of protein biomarkers. , , Eliminate e...electivity and sensitivity. , Build methods quick...
...nce of the LTQ, incorporating more techniques to g...ntifics innovations in ion trap technology. Therm...r that offers multiple dissociation techniques, PQ...iation (PQD) is a patented technique that eliminat...
Biology Products: